Companies › Neurocrine Biosciences
6 active drug programs in 17 registered trials: 11 Phase 3, 5 Phase 2, 1 Phase 4; Psychiatry, Neurology, Genitourinary; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Valbenazine Synaptic vesicular amine transporter inhibitor | SLC18A2 | Phase 4 | Schizophrenia; Trichotillomania (Hair-Pulling Disorder); Cervical Dystonia | Jun 2028 |
| Osavampator (NBI-1065845) Glutamate receptor ionotropic AMPA positive allosteric modulator | GRIA4, GRIA3, GRIA2, GRIA1 | Phase 3 | Major Depressive Disorder | Jul 2027 |
| Crinecerfont Corticotropin releasing factor receptor 1 antagonist | CRHR1 | Phase 3 | Congenital Adrenal Hyperplasia | Aug 2027 |
| NBI-1117568 | – | Phase 3 | Schizophrenia; Bipolar I Disorder | Oct 2027 |
| NBI-1065890 Vesicular monoamine transporter 2 (VMAT2) inhibitor | VMAT2 | Phase 2 | Tardive Dyskinesia | Feb 2027 |
| NBI-1117570 | – | Phase 2 | Schizophrenia | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07365462 | NBI-1065890 | Phase 2 | Tardive Dyskinesia | Neurology | Feb 2027 |
| NCT05207085 | Valbenazine | Phase 2 | Trichotillomania (Hair-Pulling Disorder) | Psychiatry | Feb 2027 |
| NCT06771323 | Valbenazine | Phase 2 | Cervical Dystonia | Neurology | Jun 2027 |
| NCT06786624 | Osavampator (NBI-1065845) | Phase 3 | Major Depressive Disorder | Psychiatry | Jul 2027 |
| NCT06911112 | Osavampator (NBI-1065845) | Phase 3 | Major Depressive Disorder | Psychiatry | Jul 2027 |
| NCT06963021 | Osavampator (NBI-1065845) | Phase 3 | Major Depressive Disorder | Psychiatry | Jul 2027 |
| NCT04490915 | Crinecerfont | Phase 3 | Congenital Adrenal Hyperplasia | Genitourinary | Aug 2027 |
| NCT04806451 | Crinecerfont | Phase 3 | Congenital Adrenal Hyperplasia | Genitourinary | Aug 2027 |
| NCT07288333 | NBI-1117570 | Phase 2 | Schizophrenia | Psychiatry | Aug 2027 |
| NCT06963034 | NBI-1117568 | Phase 3 | Schizophrenia | Psychiatry | Oct 2027 |
| NCT07105098 | NBI-1117568 | Phase 3 | Schizophrenia | Psychiatry | Nov 2027 |
| NCT07288320 | NBI-1117568 | Phase 2 | Bipolar I Disorder | Psychiatry | Feb 2028 |
| NCT07105111 | Valbenazine | Phase 4 | Schizophrenia | Psychiatry | Jun 2028 |
| NCT07196501 | Osavampator (NBI-1065845) | Phase 3 | Major Depressive Disorder | Psychiatry | Jul 2028 |
| NCT06966401 | Osavampator (NBI-1065845) | Phase 3 | Major Depressive Disorder | Psychiatry | May 2029 |
| NCT07227818 | NBI-1117568 | Phase 3 | Schizophrenia | Psychiatry | Jul 2029 |
| NCT07114874 | NBI-1117568 | Phase 3 | Schizophrenia | Psychiatry | Dec 2031 |
Cash and short-term investments of $738m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Alkermes Supernus Pharmaceuticals Definium Therapeutics US Intra-Cellular Therapies ACADIA Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.